Encala is a structured lipid matrix formulated of lysophosphatidylcholine monoglycerides and essential fatty acids and was developed specifically for patients with cystic fibrosis (CF)
A non-GMO, taste-neutral, gluten-free, plant-based powder designed to be mixed into meals, beverages, or snacks
Clinically proven to increase overall fat absorption, weight, and height
Supplies essential fatty acids and choline
A source of 100 healthy calories per serving
See nutrition facts and ingredient list to learn more about the benefits of Encala

Multi-Serving Pouch
Ingredients: Tapioca Maltodextrin, Monoglycerides, Soybean Lecithin, Oleic Acid and Linolenic Acid, Calcium Chloride, Water.
Contains: Soy.
Encala works in two ways:
- It provides highly absorbable fat calories and essential fatty acids to meals, beverages, or snacks.
- It helps your patient’s body absorb the fat and fat-soluble vitamins that are already in the food they’re eating.
Encala can help patients with CF who have exocrine pancreatic insufficiency (EPI)
Pancreatic enzyme replacement therapy (PERT) is a vital aspect of treatment for patients with CF because it supplies essential digestive enzymes. However, even with recommended doses of PERT, fat malabsorption often persists. Some of the ingested fat isn’t broken down and absorbed through the mucosa of the small intestine.
Despite PERT, the following issues may persist:
- Decreased bicarbonate production by the pancreas, which results in stomach acid not being completely neutralized in the small intestine
- Changes in the supply of bile acids play an important role in intestinal fat absorption
- Changes in the speed of transit of food through the small intestine
Pancreatic enzyme replacement therapy (PERT) is a vital aspect of treatment for patients with PI because it supplies essential digestive enzymes. However, even with recommended doses of PERT, fat malabsorption often persists. Some of the fat broken down by PERT is not readily absorbed through the mucosa of the small intestine.
Pancreatic lipase is not required for the digestion and absorption of the fat calories contained in Encala.1
Encala is readily absorbed through the mucosa of the small intestine and enhances the absorption of fats from the associated meal. This two-pronged approach to improving caloric absorption helps patients achieve their weight, height, and BMI goals in a healthier, easier way.
Adequate nutrition and growth depend on optimizing ingestion, digestion, and absorption
CF has a major impact on all three:
The number of calories consumed—food ingestion—needs to be increased to compensate for malabsorption of calories through the small intestine.
Digestion of key nutrients, especially fat and fat-soluble vitamins, is impaired by CF-related PI because the pancreas does not produce and secrete enough of the fat-digesting enzyme, lipase. As a result, fat cannot be fully broken down and absorbed through the intestinal wall.
Normal coefficient of fat absorption (CFA) is >93%, but in patients with CF on PERT, these levels can range from 70% to 85%.2-5 In fact, in one study, 24% of patients on PERT had CFA <85%, which was associated with significantly lower Z scores for weight.6